Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
08.10.2025 13:00
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
08.10.2025 12:42
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Medtech M&A has remained slow this year. But 2 execs are ready to make a deal
08.10.2025 09:48
Executives from Stryker and Johnson & Johnson are on the hunt for deals, despite a turbulent environment, they said at AdvaMed’s The MedTech Conference.
Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks
08.10.2025 05:43
Johnson & Johnson (NYSE:JNJ) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Johnson & Johnson (NYSE:JNJ) is one of America’s most recognizable healthcare companies, with operations that now center on pharmaceuticals and medical devices. After spinning off its consumer health unit, which included familiar names like Tylenol, Neutrogena, and Listerine, into […]
Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight
06.10.2025 17:00
The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing a significant unmet need. The development pipeline is varied, with prominent candidates including Mitsubishi Tanabe Pharma’s MT-7117, Cumberland’s ifetroban, Johnson & Johnson’s guselkumab, and Kyverna’s KYV-101. The dcSSc market is anticipated to move toward earlier intervention with targeted thera
How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
06.10.2025 12:32
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.
Did U.S. Orthopaedic Partners’ Medtech Deal Just Shift Johnson & Johnson’s (JNJ) Investment Narrative?
06.10.2025 12:20
In the past week, U.S. Orthopaedic Partners announced a collaboration with Johnson & Johnson, selecting the medtech company as its official vendor for total joint products across its clinical platform after a surgeon-led evaluation of product performance and durability. This agreement not only grants USOP access to advanced solutions such as the VELYS Robotic-Assisted Solution but also highlights a growing industry trend where physician-led management organizations collaborate closely with...
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
06.10.2025 12:07
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
Basil Systems Launches Safety Signaling Solution to Proactively Detect and Prevent Medical Device Risks
06.10.2025 12:00
BOSTON, October 06, 2025--Basil Systems Launches Safety Signaling Solution to Proactively Detect and Prevent Medical Device Risks
Johnson & Johnson (JNJ) Gains FDA Nod for TREMFYA Subcutaneous Therapy
02.10.2025 06:55
Johnson & Johnson (NYSE:JNJ) ranks among the top picks for a retirement portfolio. On September 26, Johnson & Johnson (NYSE:JNJ) reported that the US FDA had approved a subcutaneous induction protocol of TREMFYA (guselkumab) for the treatment of individuals with moderate to severe active ulcerative colitis. With this approval, TREMFYA becomes the first IL-23 inhibitor […]
GCC Liquid Biopsy Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Bio-Rad, Thermo Fisher Scientific, Johnson & Johnson, Guardant Health, QIAGEN, Sysmex
01.10.2025 11:37
The GCC Liquid Biopsy Market is projected to grow from US$ 98.24 million in 2024 to US$ 309.53 million by 2033, at a CAGR of 13.60%. This rapid growth is driven by rising cancer incidence, advances in genomics technology, increased healthcare spending, and government support for precision medicine. Liquid biopsies offer a non-invasive alternative to tissue biopsies, allowing for early cancer detection and personalized treatment. Despite challenges like high costs and regulatory hurdles, the mark
Bristol Myers, Takeda to pool data for AI-based drug discovery
01.10.2025 09:31
(Reuters) -Bristol Myers Squibb, Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development. The companies are joining a consortium that includes AbbVie and Johnson & Johnson , and will contribute data from several thousand experimentally determined protein–small molecule structures to train an AI model called OpenFold3, life sciences company Apheris said on Wednesday. The initiative is based on a federated data sharing model, which enables collaboration without exposing sensitive data.
Should You Buy Kenvue Stock After Its 30% Plunge?
01.10.2025 08:44
There hasn't been much good news lately for this Johnson & Johnson spinoff.
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
29.09.2025 14:56
Genmab, on Monday, announced its plan to buy Merus for about $8 billion. The news sent Merus stock into the stratosphere.
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
29.09.2025 12:00
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of children six years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis (PsO), who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis (PsA). This milestone makes TREMFYA® the first and only IL-23 inhibitor approved for these pediatric indications and builds on the initial FDA approvals in
Jim Cramer Discusses Kenvue Inc. (KVUE) & Legal Issues
26.09.2025 12:55
We recently published 14 Stocks Jim Cramer Discussed Including His 2 Top Quantum Computing Stocks. Kenvue Inc. (NYSE:KVUE) is one of the stocks Jim Cramer recently discussed. Kenvue Inc. (NYSE:KVUE) has been in the news lately after President Trump asserted that taking Tylenol can increase autism in unborn children. The firm’s shares have lost 22% […]
What to Expect From Johnson & Johnson’s Q3 2025 Earnings Report
26.09.2025 12:11
Johnson & Johnson is expected to release its fiscal third-quarter earnings next month, and analysts project a double-digit earnings rise.
Could This Single Dividend King Make Your Portfolio Worth $1 Million in 20 Years?
26.09.2025 11:21
There is a lot to like about this healthcare company, but that goal might be beyond its powers.